-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 17, Milestone Pharmaceuticals, an innovative cardiovascular drug research and development company, announced that it has reached an exclusive license and cooperation agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil for paroxysmal rooms in Greater China.
Patients with superior tachycardia (paroxysmal supraventricular tachycardia, PSVT) and other cardiovascular diseases
.
Etripamil is Milestone’s main research product and is a new type of calcium channel blocker designed to provide a rapid response treatment for occasional cardiovascular diseases
.
According to the terms of the agreement, Milestone will grant Ji Xing the exclusive license to develop and commercialize etripamil for PSVT patients in Greater China
.
Milestone will receive a US$15 million down payment from Jixing and a US$5 million equity investment from RTW